Assessing Risk Across the Spectrum of Patients with the Metabolic Syndrome
- 1 August 2005
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 96 (4), 8-10
- https://doi.org/10.1016/j.amjcard.2005.05.007
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalitiesCurrent Opinion in Cardiology, 2005
- National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart StudyCirculation, 2004
- Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetesCurrent Opinion in Cardiology, 2004
- Cardiovascular Disease Risk Factors Predict the Development of Type 2 DiabetesDiabetes Care, 2004
- Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic ResonanceDiabetes, 2003
- The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged MenJAMA, 2002
- Statin use in acute coronary syndromes: cellular mechanisms and clinical evidenceCurrent Opinion in Lipidology, 2002
- Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in WomenCirculation, 2002
- Nuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health StudyArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trialThe American Journal of Cardiology, 2002